Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability

Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer

(2010) David J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy

(2009) G. Sonpavde et al.   ANNALS OF ONCOLOGY

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors

(2009) E. B. Golden et al.   BLOOD

Bortezomib and EGCG: no green tea for you?

(2009) J. J. Shah et al.   BLOOD

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

(2009) S Novello et al.   BRITISH JOURNAL OF CANCER

Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions

(2009) A. S. Tsao et al.   Cancer Prevention Research

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

(2009) B. I. Rini et al.   CLINICAL CANCER RESEARCH

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

(2009) Walid S. Kamoun et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic inhibition of head and neck tumor growth by green tea (−)‐epigallocatechin‐3‐gallate and EGFR tyrosine kinase inhibitor

(2008) Xin Zhang et al.   INTERNATIONAL JOURNAL OF CANCER